Guggenheim Rates Illumina (ILMN) buy, $200 Price Target

Analyst Subbu Nambi of Guggenheim maintained a buy rating on Illumina, Inc. with a $200 price target, a 13.75% upside from the current price.

By EarningsIQ Research Desk · Published Jun 29, 2026, 10:00 AM EDT · Updated Jul 1, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Guggenheim rated Illumina, Inc. ($ILMN) "buy" with a $200 price target on June 29, 2026.

Since the rating, $ILMN is up 7.3% after 1 week, up 7.6% after 1 month and up 45.0% to date (from the $181.10 close on Jun 29, 2026).

ILMN Illumina, Inc.

$262.54 +95.41% year to date

Daily close · Oct 16, 2026

Key Points

Guggenheim analyst Subbu Nambi reiterated a buy rating on Illumina, Inc. (NasdaqGS: ILMN) with a price target of $200 on June 29, 2026.
Guggenheim's $200 price target implies 13.75% upside from Illumina, Inc.'s ($ILMN) current $175.83 share price.
Illumina shares trade around $175.83, sitting below its 50-day moving average of $205.03 while staying above its 200-day moving average of $156.62.
A total of 20 analyst opinions back a consensus buy recommendation for the company, backed by a mean target price of $202.65.

Get $ILMN trade alerts by text

We text you when insiders, Congress or big funds trade $ILMN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Illumina, Inc. alert may contain errors. Disclosures

Guggenheim Reaffirms Buy Stand on Illumina

Guggenheim analyst Subbu Nambi kept a buy rating on Illumina, Inc. (NasdaqGS: ILMN) on June 29, 2026, pointing to a price target of $200. The firm continues to show confidence in the genetic analysis leader as adoption of its sequencing systems grows across research centers and clinical labs worldwide.

Stock Price Levels and Trading Range

Illumina shares recently changed hands at $175.83. The stock moves within a 52-week band stretching from a low of $88.00 to a high of $250.06. Shares currently sit below the 50-day moving average of $205.03 while holding above the 200-day moving average of $156.62. The company commands a market value of roughly $36.06 billion.

12-month forecast

$ILMN price target

Illumina, Inc. daily closes and this analyst's $200 target. Not advice.

Analysts Set New Price Targets

Wall Street firms have kept a close eye on the life sciences company through the autumn months. On October 13, 2026, TD Cowen maintained its hold rating while lifting its target to $270.00 from $210.00. Barclays kept an underweight rating on October 7, 2026, adjusting its target to $200.00 from $160.00. RBC Capital maintained an outperform rating on October 5, 2026, moving its target to $310.00 from $230.00. Guggenheim also maintained a buy rating on October 1, 2026, pushing its target to $305.00 from $226.00. Leerink Partners kept an outperform rating on September 29, 2026, raising its target to $300.00 from $220.00. Piper Sandler maintained an overweight rating on September 28, 2026, with a target of $305.00 raised from $225.00. Earlier, UBS upgraded the stock to a buy on September 9, 2026, setting a $260.00 target, and Argus Research maintained a buy rating on September 3, 2026, with a $235.00 target. Across 20 analyst opinions, the company holds a consensus buy recommendation with a mean price target of $202.65.

Core Business and Genomic Solutions

Headquartered in San Diego, California, Illumina builds sequencing and array tools for genetic and genomic analysis. Its core products include instruments, consumables, reagents, and flow cells used by academic institutions, government labs, hospitals, and biotech firms for whole-genome sequencing and targeted resequencing applications. The company employs about 8,600 people and partners with organizations like Labcorp Holdings Inc. to advance oncology treatments.

Upcoming Financial Milestones

Investors will watch for the company's next earnings report scheduled for October 29, 2026, to check updated revenue and profit figures. Guggenheim's latest note reflects ongoing attention to the company's long-term position in molecular diagnostics without giving financial advice.